Developing Next-generation Cancer Treatments

Therapeutic Portfolio

When highly energetic alpha particles pass through a cancer cell they deliver enormous damage. Targeted Alpha Therapy harnesses the power of alpha particles by attaching alpha emitting isotopes to highly specific targeting molecules that deliver the radiation directly to cancer cells.
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.

Prostate Cancer




Pancreatic and Breast Cancer

Delivering an Unmatched
Supply of Alpha Isotopes


Alpha 212 is the isotope Lead-212 or ²¹²Pb and powers AdvanCell's therapeutic pipeline.

AdvanCell routinely manufactures Alpha 212 through a fleet of ²¹²Pb Generators enabling full control of the supply chain for the global manufacture of targeted alpha therapies.

Isotope Pipeline

AdvanCell is significantly increasing the adoption of Targeted Alpha Therapy by providing a scalable supply of the isotopes required to make these therapies a reality for every patient.

The AdvanCell ²¹²Pb Generator

Our proprietary manufacturing platform capable of delivering a scalable solution to fully automated, GMP compliant manufacture of alpha radioligand therapies.

The award winning AdvanCell ²¹²Pb Generator produces a scalable supply of Alpha 212, a proprietary alpha isotope used in Targeted Alpha Therapy.

The generator provides an unmatched, GMP compatible, manufacturing platform to support rapid clinical development of alpha radioligand therapies.


The generator can be installed in a GMP manufacturing environment and flexibly deliver clinical scale ²¹²Pb every day on an ongoing basis.


Multiple generators can be operated in series providing the ability to safely scale production as required.


The generator produces a consistently radioisotopically pure product giving high quality assurance.